Omthera Investor Challenges $443M AstraZeneca Buyout
An Omthera Pharmaceuticals Inc. shareholder launched a putative class action in Delaware Chancery Court on Friday aimed at blocking AstraZeneca PLC's planned buyout, saying the deal — worth up to $443...To view the full article, register now.
Already a subscriber? Click here to view full article